SCHEMBL6528192

SCHEMBL6528192

O=C(CC1NC(=O)NC1=O)NCCc1ccc(-c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.60
KDM4E B2RXH2 4/20 0.60
HSD17B10 Q99714 4/20 0.60
HPGD P15428 3/20 0.60
MAPT P10636 2/20 0.60
POLB P06746 2/20 0.60
MAPK1 P28482 1/20 0.60
TAAR1 Q96RJ0 1/20 0.59
EPHX2 P34913 5/20 0.53
LTA4H P09960 4/20 0.53
GAA P10253 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HTT P42858 1/20 0.50
PLAAT3 P53816 2/20 0.46
PLAAT5 Q96KN8 2/20 0.46
PLAAT2 Q9NWW9 2/20 0.46
PLAAT4 Q9UL19 2/20 0.46
RECQL P46063 1/20 0.45
ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875788 0.97 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2869386 0.91 ALDH1A1 (0.67) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2870661 0.91 ALDH1A1 (0.67) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2874169 0.89 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2874485 0.88 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2872656 0.87 ALDH1A1 (0.72) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2865063 0.87 ALDH1A1 (0.60) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2873310 0.87 ALDH1A1 (0.57) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2867675 0.86 KDM4E (0.54) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2874358 0.85 ALDH1A1 (0.56) ALDH1A1KDM4EHSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 MMP12, PDE12, MMP13 ALDH1A1 441/4885KDM4E 553/4885HSD17B10 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.